To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

NCT04253236 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Warm Autoimmune Hemolytic Anemia

Interventions

DRUG: RVT-1401 680 mg/weekly
DRUG: RVT-1401 340 mg/weekly

Sponsor

Immunovant Sciences GmbH